Novo Nordisk's (NVO.US) weight loss drug is available in all doses in the U.S. and could help it get off the FDA's shortage list.

Zaijiu Finance learned that the latest drug shortage database released by the US Food and Drug Administration (FDA) on Wednesday shows that all doses of Novo Nordisk's (NVO.US) popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the US. This suggests that Novo Nordisk's efforts to increase its weekly drug supply are beginning to bear fruit as demand in the US market continues to soar.